COOPERATIVE TISSUE BANK OF HIV POSITIVE MALIGNANCIES

{\rtf1\ansi\ansicpg1252\deff0\deflang1033{\fonttbl{\f0\fswiss\fcharset0字体；}} 美国国立癌症研究所(NCI)的艾滋病和癌症标本资源(ACSR) 计划，向资助/批准的癌症研究人员提供与艾滋病毒/艾滋病相关的恶性组织和数据 促进全球了解艾滋病毒感染和某些癌症之间的关系。中等标准杆 地区ACSR(MR-ACSR)联盟，包括：俄亥俄州立大学(OSU)、埃默里大学、Rush\PAR 大学、田纳西大学孟菲斯分校以及乌干达和肯尼亚的东非分支机构提议\PAR (具体目标1)与附属公司维护符合所有\PAR标准的中区ACSR(MR-ACSR)生物存储库 ACSR规则和建议，包括NCI生物质学资源和\PAR的最佳实践 适用的联邦法规，并与运营办公室进行适当的组织，以执行\par 收集、增强、存储和分发与艾滋病毒相关的、质量有保证的人的主要任务 具有相关临床、病理、视觉和人口学数据的肿瘤组织\par 调查人员。为了确保这些资源的最佳利用，MR-ACSR建议(具体目标2)合作 使用ACSR区域生物信息库、NCI AIDS恶性项目(AMP)和其他与NCI AIDS相关的\par 恶性肿瘤和癌症生物信息库计划和俄亥俄州立大学病理学系 人类组织资源网络(HTRN)利用高质量的样本和数据可用性进行翻译\PAR 艾滋病毒/艾滋病相关恶性肿瘤领域的研究。要完成NCI的总体目标，以达到 为了促进健康，MR-ACSR必须(具体目标3)开发原创和创新的计划，以 利用实验室\PAR提高生物样品和相关数据的质量、可用性和相关性 MR-ACSR财团的设施和标本资源，包括东非分支机构、俄亥俄州\PAR 州立大学病理学系HTRN和生物医学信息学系CABIG\PAR 项目。MR-ACSR建议部署一种新的组织固定方法来改善PAR的保存 用于研究组织的RNA、DNA和组织蛋白。可以部署组织微阵列(TMA)构建\par 使用便于在资源受限的\par中收集诊断样本的“现场”构造格式 地点。我们建议使用PAR来促进撒哈拉以南非洲淋巴瘤(NHL)的组织表型 用这种TMA形式进行后续的远距离处理和免疫组织化学染色。MR-ACSR也是 具有支持数字显微镜的设施，可使用\PAR的数字化图像进行远程可视互联网会诊 用于与我们在东非的合作者共享数据的组织，特别是与诊断咨询和\PAR相关的数据 肿瘤临床治疗试验中的病理组织综述。最后，为了最大限度地利用可视化数据和\par 远程协作，MR ACSR建议与caGrid的开发人员合作，作为\PAR的临床资源 数字图像数据。\fs20\par \标准杆 }

{\rtf1\ansi\ansicpg1252\deff0\deflang1033{\fonttbl{\f0\fswiss\fcharset0 Arial;}} {\*\generator Msftedit 5.41.15.1515;}\viewkind4\uc1\pard\f0\fs21 The AIDS and Cancer Specimen Resource (ACSR) of the National Cancer Institutes (NCI) AIDS Malignancy\par Program, provides HIV/AIDS-related malignant tissues and data to funded/approved cancer researchers to\par promote a global understanding of the relationships between HIV infection and certain cancers. The Mid\par Region ACSR (MR-ACSR) consortium, including: The Ohio State University (OSU), Emory University, Rush\par University, University of Tennessee, Memphis, and East African affiliates in Uganda and Kenya, proposes to\par (specific aim 1) maintain a mid-region ACSR (MR-ACSR) biorepository with affiliates that is compliant with all\par ACSR rules and recommendations including the NCI Best Practices for Biospecimen Resources and\par applicable federal regulations and is adequately structured with an Operations Office to perform the\par principal tasks of collecting, enhancing, storing, and distributing HIV-related, quality assured human\par tumor tissue with associated clinical, pathological, visual and demographic data to approved\par investigators. To assure best use of these resources the MR-ACSR proposes to (specific aim 2) collaborate\par with ACSR regional biorepositories, NCI AIDS Malignancy Program (AMP) and other NCI AIDS related\par malignancy and cancer biorepository programs and The Ohio State University Department of Pathology's\par Human Tissue Resource Network (HTRN) to leverage quality specimen and data availability for translational\par research in area of HIV/AIDS-related malignancies. To accomplish the overall objectives of the NCI to\par promote good health, the MR-ACSR must (specific aim 3) develop original and innovative programs to\par improve the quality, availability and relevance of biospecimens and associated data using the laboratory\par facilities and specimen resources of the MR-ACSR consortium including the East African affiliates, The Ohio\par State University Department of Pathology's HTRN and the Department of Biomedical Informatics caBIG\par project. MR-ACSR proposes the deployment of a new tissue fixation method to improve preservation of\par RNA, DNA and tissue proteins for research tissues. Tissue microarray (TMA) construction can be deployed\par using a "field" construction format that facilitates diagnostic specimen collection in resource constrained\par locations. We propose to facilitate the tissue phenotyping of lymphoma (NHL) in sub-Saharan Africa using\par this TMA format with follow up distant processing and immunohistochemical staining. The MR-ACSR also\par has a supporting digital microscopy facility for remote visual Internet consultation using digitized images of\par tissue for data sharing with our collaborators in East Africa, particularly related to diagnostic consultation and\par review of pathology tissues in cancer clinical treatment trials. Finally, to make the best use of visual data and\par distant collaboration, the MR ACSR proposes to work with the developers of caGrid as a clinical resource for\par digital image data.\fs20\par \par }